^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    AKAP13 (A-Kinase Anchoring Protein 13)

    i
    Other names: AKAP13, A-Kinase Anchoring Protein 13, AKAP-Lbc, BRX, Lymphoid Blast Crisis Oncogene, PROTO-LB, ARHGEF13, C-Lbc, Ht31, HA-3, LBC, Breast Cancer Nuclear Receptor-Binding Auxiliary Protein, Non-Oncogenic Rho GTPase-Specific GTP Exchange Factor, Guanine Nucleotide Exchange Factor Lbc, Protein Kinase A-Anchoring Protein 13, Human Thyroid-Anchoring Protein 31, A Kinase (PRKA) Anchor Protein 13, A-Kinase Anchor Protein 13, LBC Oncogene, AKAP-13, PRKA13, P47, PROTO-LBC, HT31
    Associations

    News

    Trials
    2ms
    Targeting the FBXW7-AKAP13-YAP axis suppresses gliomagenesis by dual inhibition of tumor invasion and macrophage recruitment. (PubMed, Biochem Pharmacol)
    We further identified F-box and WD repeat domain-containing 7 (FBXW7) as an upstream regulator that promotes ubiquitin-mediated degradation of AKAP13. Together, our findings reveal a novel FBXW7/AKAP13/YAP/chemokine signaling axis that promotes glioma pathogenesis through both tumor-autonomous invasion and TAM recruitment, highlighting a promising therapeutic target for this lethal malignancy.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7) • CSF1 (Colony stimulating factor 1) • CCL2 (Chemokine (C-C motif) ligand 2) • AKAP13 (A-Kinase Anchoring Protein 13)
    11ms
    Adrenal mixed corticomedullary tumors: report of a case with molecular characterization and systematic review. (PubMed, Virchows Arch)
    Most MCMTs are benign, but aggressive behavior was detected in four (12%) cases, all of them showing large size (80-220 mm), poor delimitation, venous invasion, necrosis, and/or high proliferation rates. The pathogenesis is unknown, but our findings suggest a tumor histogenesis from the cortical cellular component through the regulation of the protein kinase A pathway and secondary proliferation of the medullary component.
    Journal
    |
    SSTR (Somatostatin Receptor) • EPAS1 (Endothelial PAS domain protein 1) • SSTR2 (Somatostatin Receptor 2) • GNAS (GNAS Complex Locus) • MLANA (Melan-A) • GATA3 (GATA binding protein 3) • AKAP13 (A-Kinase Anchoring Protein 13)
    over1year
    Exploring prognostic DNA methylation genes in bladder cancer: a comprehensive analysis. (PubMed, Discov Oncol)
    Finally, drug sensitivity analysis of Nomogram model genes was conducted based on the CMap database, followed by molecular docking experiments. Our research offers a reference and theoretical basis for prognostic evaluation, drug selection, and understanding the impact of DNA methylation changes on the prognosis of BLCA.
    Journal • Epigenetic controller
    |
    TAP1 (Transporter 1) • AKAP13 (A-Kinase Anchoring Protein 13)
    almost2years
    RET Fusion Testing in Patients With NSCLC: The RETING Study. (PubMed, JTO Clin Res Rep)
    In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of RET fusions in patients with NSCLC. The likelihood of RET false-negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC.
    Journal
    |
    RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6) • AKAP13 (A-Kinase Anchoring Protein 13)
    |
    RET fusion • RET positive
    over2years
    The Tetraspanin CD9 Shapes Glucocorticoid Sensitivity in Pediatric B-Precursor Acute Lymphoblastic Leukemia (ASH 2023)
    Ex vivo drug sensitivity profiling to prednisone (Pred) and dexamethasone (Dex) was performed on 6 BCP-ALL cell lines and 18 patient samples with differential CD9 expression. This study provides a definitive linkage of CD9 with GC sensitivity in childhood BCP-ALL mediated through a NR3C1-independent mechanism. CD9- cases could be prone to trametinib combination therapy, whereas CD9+ cases might need a third drug such as ruxolitinib to counteract GC resistance.
    Clinical
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD9 (CD9 Molecule) • AKAP13 (A-Kinase Anchoring Protein 13)
    |
    CD9 expression
    |
    Mekinist (trametinib) • Jakafi (ruxolitinib) • prednisone • dexamethasone
    over2years
    Clinical impact of mixed pulmonary carcinoma and carcinoid: the driver from their mono-clonal origin. (PubMed, Virchows Arch)
    Moreover, the same mutation was detected in the metastasis constituted only by AC (cases 2 and 4). Although it is a rare malignancy in the lung, mixed LUA and TC/AC could be included among the histotypes for which a deep molecular characterization of both components is needed to identify the presence of potential druggable genetic alterations.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • RET (Ret Proto-Oncogene) • AKAP13 (A-Kinase Anchoring Protein 13)
    |
    KRAS mutation • RET fusion
    over2years
    GERMLINE GENETIC VARIANTS IN APPARENTLY SPORADIC DIFFERENTIATED THYROID CANCER (ATA 2023)
    These data suggest that DTC has a strong genetic predisposition than generally appreciated. Variants in well‐known cancer genes are frequent and may have primary or auxiliary roles in the pathogenesis of DTC.
    Late-breaking abstract
    |
    PTEN (Phosphatase and tensin homolog) • FGFR4 (Fibroblast growth factor receptor 4) • CHEK2 (Checkpoint kinase 2) • WRN (WRN RecQ Like Helicase) • SALL4 (Spalt Like Transcription Factor 4) • FOXA3 (Forkhead Box A3) • PRF1 (Perforin 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SMARCD3 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 3) • AKAP13 (A-Kinase Anchoring Protein 13) • CDH11 (Cadherin 11) • EIF6 (Eukaryotic Translation Initiation Factor 6) • LZTR1 (Leucine Zipper Like Transcription Regulator 1) • RNF169 (Ring Finger Protein 169) • TMCC1 (Transmembrane And Coiled-Coil Domain Family 1)